Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics|
|Author:||Van Sebille, Y.|
|Citation:||Current Oncology Reports, 2015; 17(11):50-1-50-8|
|Ysabella Z. A. Van Sebille, Romany Stansborough, Hannah R. Wardill, Emma Bateman, Rachel J. Gibson, Dorothy M. Keefe|
|Abstract:||Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. New emerging areas of research have been proposed to play key roles in the development of mucositis, providing rationale for potential new therapeutics for the prevention, treatment or management of chemotherapy-induced mucositis. This review aims to address these new areas of research and to comment on the therapeutics arising from them.|
|Keywords:||Mucositis; Toxicity; Chemotherapy-induced gut toxicity; Cancer side effects; Zinc sulphate; Palifermin; R-spondin1; Benzydamine hydrochloride (HCl); Probiotics; Antimicrobials; Antioxidants; Analgesics; Coating agents; Mucositis treatment|
|Description:||This article is part of the Topical Collection on Palliative Medicine|
|Rights:||© Springer Science+Business Media New York 2015|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.